Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de David Chang
Age : 61
Public asset : 44,749,821 USD
Country of residence : Unknown
Linked companies : Allogene Therapeutics, Inc. - Peloton Therapeutics, Inc.

Biography of David Chang 
Dr. David D. Chang is a President, Chief Executive Officer & Director at Allogene Therapeutics, Inc., a Director & Venture Partner at Vida Ventures LLC, a Venture Partner at Two River Consulting LLC, a Board Observer at Cell Design Labs, Inc., a Venture Partner at Two River Group Holdings LLC and a Venture Partner at VV Manager LLC. He is on the Board of Directors at Allogene Therapeutics, Inc., Peloton Therapeutics, Inc., Vida Ventures LLC, A2 Biotherapeutics, Inc. and IconOVir Bio, Inc. Dr. Chang was previously employed as a Chief Medical Officer, EVP-Research & Development by Kite Pharma, Inc., a Vice President-Global Development by Amgen, Inc., and an Associate Professor by David Geffen School of Medicine. He received his undergraduate degree from Massachusetts Institute of Technology and a doctorate degree from Stanford University.


Current positions of David Chang 
Holdings of David Chang 
David Chang : Personal Network 
Most Read News 
05/11CATHIE WOOD : Tumble in Coinbase pushes Wood's ARK fund closer to pandemic low
RE
05/12MASAYOSHI SON : SoftBank Vision Fund posts $26 billion loss; Son pledges defence
RE
05/14ELON MUSK : Elon Musk says Twitter legal team told him he violated an NDA
RE
05/11ELON MUSK : Musk's delay in disclosing Twitter stake triggers SEC probe - WSJ
RE
05/20XAVIER NIEL : UWR shares spike as billionaire Xavier Niel discloses 27% stake
RE
05/19ELON MUSK : Musk says 'Tesla is on my mind 24/7' amid concerns about Twitter distraction
RE
05/10ELON MUSK : Elon Musk says Tesla open to buying a mining company
RE
05/17ELON MUSK : Prominent hedge funds invested in Twitter before Musk unveiled plans
RE
05/17JPMorgan shareholders vote disapproval of CEO Dimon's special payout
RE
05/09ELON MUSK : Musk tweet on Japan doomed by low birthrate provokes anger - but not just at him
RE
More news


© 2022 People and Ownership :   
David Chang : Connections 


Latest news about David Chang 
05/18Cabaletta Bio Says DSG3-CAART Interim Data Show 'Favorable Safety Profile' in Autoimmune Skin Disease
MT
05/04TRANSCRIPT : Allogene Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
04/14Allogene Therapeutics Unveils Cell Forge 1, A Uniquely Designed Manufacturing Facility to Deliver Allocar T Products
CI
04/07TRANSCRIPT : The Howard Hughes Corporation - Analyst/Investor Day
CI
03/03TRANSCRIPT : Sweetgreen, Inc., Q4 2021 Earnings Call, Mar 03, 2022
CI
02/23TRANSCRIPT : Allogene Therapeutics, Inc., Q4 2021 Earnings Call, Feb 23, 2022
CI
01/11TRANSCRIPT : Allogene Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-11-2022 03:45 PM
CI
More news